Physiology and pharmacology of alcohol: the imidazobenzodiazepine alcohol antagonist site on subtypes of GABAA receptors as an opportunity for drug development?
Alcohol (ethanol, EtOH) has pleiotropic actions and induces a number of acute and long-term effects due to direct actions on alcohol targets, and effects of alcohol metabolites and metabolism. Many detrimental health consequences are due to EtOH metabolism and metabolites, in particular acetaldehyde, whose high reactivity leads to nonspecific chemical modifications of proteins and nucleic acids. Like acetaldehyde, alcohol has been widely considered a nonspecific drug, despite rather persuasive evidence implicating inhibitory GABA(A) receptors (GABA(A)Rs) in acute alcohol actions, for example, a GABA(A)R ligand, the imidazobenzodiazepine Ro15-4513 antagonizes many low-to-moderate dose alcohol actions in mammals. It was therefore rather surprising that abundant types of synaptic GABA(A)Rs are generally not responsive to relevant low concentrations of EtOH. In contrast, delta-subunit-containing GABA(A)Rs and extrasynaptic tonic GABA currents mediated by these receptors are sensitive to alcohol concentrations that are reached in blood and tissues during low-to-moderate alcohol consumption. We recently showed that low-dose alcohol enhancement on highly alcohol-sensitive GABA(A)R subtypes is antagonized by Ro15-4513 in an apparently competitive manner, providing a molecular explanation for behavioural Ro15-4513 alcohol antagonism. The identification of a Ro15-4513/EtOH binding site on unique GABA(A)R subtypes opens the possibility to characterize this alcohol site(s) and screen for compounds that modulate the function of EtOH/Ro15-4513-sensitive GABA(A)Rs. The utility of such drugs might range from novel alcohol antagonists that might be useful in the emergency room, to drugs for the treatment of alcoholism, as well as alcohol-mimetic drugs to harness acute positive effects of alcohol.
Wallner
M
M
Department of Molecular and Medical Pharmacology, University of California, Los Angeles, CA 90095-1735, USA. mwallner@mednet.ucla.edu
Olsen
R W
RW
D000079:Acetaldehyde / Q000378:metabolism; D000437:Alcoholism / Q000188:drug therapy* / Q000378:metabolism; D000818:Animals; D001386:Azides / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D016739:Behavior, Addictive / Q000188:drug therapy* / Q000378:metabolism; D001569:Benzodiazepines / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D001667:Binding, Competitive; D002492:Central Nervous System Depressants / Q000009:adverse effects* / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D015195:Drug Design; D000431:Ethanol / Q000009:adverse effects* / Q000378:metabolism; D018756:GABA Antagonists / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D058787:GABA-A Receptor Antagonists; D006801:Humans; D011485:Protein Binding; D011963:Receptors, GABA-A / Q000378:metabolism
D001386:Azides; D002492:Central Nervous System Depressants; D018756:GABA Antagonists; D058787:GABA-A Receptor Antagonists; D011963:Receptors, GABA-A; D001569:Benzodiazepines; D000431:Ethanol; C042957:Ro 15-4513; D000079:Acetaldehyde